S&P 500
5,970.37
+0.6%
+$34.43
DJI
42,519.64
+0.5%
+$214.16
NASDAQ
19,398.96
+0.8%
+$156.34
Bitcoin
105,366.00
+0.0%
+28.25
AAPL
$203.38
+0.8%
+$1.68
AMZN
$205.89
-0.4%
-$0.76
GOOG
$167.85
-1.5%
-$2.52
META
$667.31
-0.5%
-$3.59
MSFT
$463.24
+0.3%
+$1.28
NVDA
$141.38
+2.9%
+$4.00
TSLA
$344.95
+0.7%
+$2.26
BioLineRx (NASDAQ: BLRX)
$4.33
(5.6%)
$0.23
Price as of June 3, 2025, 3:45 p.m. ET
BioLineRx Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
BioLineRx Company Info
BioLineRx Ltd. is a clinical stage biopharmaceutical company, which engages in the research and development of treatments that focus on cancer. Its product pipeline includes Motaxafortide (BL-8040), which is used for stem-cell mobilization, solid tumors, and acute myeloid lukemia; and AGI-134, which is an immunotherapy treatment used for multiple solid tumors. The company was founded in 2003 and is headquartered in Modi'in, Israel.
News & Analysis
No articles found.
Valuation
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.